For example, one phase 2–3 RCT (NCT0578576) was registered to compare the efficacy of dual blockades of LAG‐3 and PD‐1 vs anti‐PD‐1 monotherapy in advanced NSCLC patients with PD‐L1 ≥ 50%. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.